Form 4 for KRSA Korsana Biosciences, Inc.
Accepted 2023-05-22 00:00:00 ET · period of report 2023-05-19 · accession 0001140361-23-026101 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-05-22 | 2023-05-19 | KRSA | Hecht Peter M | CEO, Dir, 10% | A - Grant | $8.68 | +225.0K | 327.4K | +220% | +$1.95M |
| D | 2023-05-22 | 2023-05-19 | KRSA | Hecht Peter M | CEO, Dir, 10% | A - Grant | $8.68 | +351.0K | 351.0K | New | +$3.05M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-19 | A | A | 225,000 | $8.68 | 327,385 | D | — | — | (F1) On May 19, 2023, the reporting person purchased directly from the Issuer 225,000 shares of Common Stock and 351,037 shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") for a total purchase price of approximately $5,000,000 (or $8.68 per share) in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 31, 2023 between the reporting person and the Issuer. The Series A Preferred Stock may be converted to Common Stock on a one-for-one basis at the option of the holder thereof. The reporting person has agreed not to convert his Series A Preferred Stock to the extent such conversion would require shareholder approval pursuant to Nasdaq listing rules and such shareholder approval has not been obtained. |
| 2 | Derivative | Series A Convertible Preferred Stock | 2023-05-19 | A | A | 351,037 | $8.68 | 351,037 | D | $0.00 · — to — | 351,037 Common Stock | (F1) On May 19, 2023, the reporting person purchased directly from the Issuer 225,000 shares of Common Stock and 351,037 shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") for a total purchase price of approximately $5,000,000 (or $8.68 per share) in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 31, 2023 between the reporting person and the Issuer. The Series A Preferred Stock may be converted to Common Stock on a one-for-one basis at the option of the holder thereof. The reporting person has agreed not to convert his Series A Preferred Stock to the extent such conversion would require shareholder approval pursuant to Nasdaq listing rules and such shareholder approval has not been obtained. |